Trials for neurodegenerative diseases: time to innovate.
作者信息
Mehta Arpan R, Chataway Jeremy, Pal Suvankar, Parmar Mahesh K B, Chandran Siddharthan
出版信息
Lancet Neurol. 2021 Dec;20(12):984. doi: 10.1016/S1474-4422(21)00388-4.
Abstract
摘要
相似文献
1
Trials for neurodegenerative diseases: time to innovate.神经退行性疾病的试验：是时候创新了。
Lancet Neurol. 2021 Dec;20(12):984. doi: 10.1016/S1474-4422(21)00388-4.
2
[Paradigm shift in clinical trials for neurodegenerative diseases].[神经退行性疾病临床试验中的范式转变]
Brain Nerve. 2007 Apr;59(4):367-74.
3
Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future.神经退行性疾病的疾病修饰治疗的临床试验：挑战与未来。
Nat Med. 2010 Nov;16(11):1223-6. doi: 10.1038/nm.2220. Epub 2010 Sep 21.
4
Gene transfer therapy for neurodegenerative disorders.神经退行性疾病的基因转移治疗
Mov Disord. 2007 Jul 15;22(9):1223-8; quiz 1369. doi: 10.1002/mds.21423.
5
Stem cell treatments for neurodegenerative diseases: challenges from a science, business and healthcare perspective.用于神经退行性疾病的干细胞治疗：从科学、商业和医疗保健角度看面临的挑战
Neurodegener Dis Manag. 2015;5(2):85-7. doi: 10.2217/nmt.15.2.
6
Fast-forwarding treatment for neurodegenerative disorders.
Lancet Neurol. 2015 Jul;14(7):687-8. doi: 10.1016/S1474-4422(15)00110-6.
7
Oxidative stress treatment for clinical trials in neurodegenerative diseases.氧化应激治疗在神经退行性疾病临床试验中的应用。
J Alzheimers Dis. 2011;24 Suppl 2:111-26. doi: 10.3233/JAD-2011-110164.
8
[Pharmacology of neurodegenerative diseases: perspectives on cellular and gene therapies].[神经退行性疾病的药理学：细胞和基因治疗的前景]
Therapie. 1998 Jan-Feb;53(1):31-4.
9
[The prospects of using the technology of genome editing for correction of neurodegenerative diseases.].[利用基因组编辑技术治疗神经退行性疾病的前景。]
Adv Gerontol. 2018;31(6):892-903.
10
Gene therapy for neurodegenerative diseases.神经退行性疾病的基因治疗。
Trends Mol Med. 2015 Aug;21(8):504-12. doi: 10.1016/j.molmed.2015.06.001. Epub 2015 Jun 26.
引用本文的文献
1
The role of placebo control in clinical trials for neurodegenerative diseases.安慰剂对照在神经退行性疾病临床试验中的作用。
Nat Med. 2023 Nov;29(11):2682-2683. doi: 10.1038/d41591-023-00080-0.
2
Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus.系统、全面、基于证据的方法来确定运动神经元病的神经保护干预措施：使用系统评价为专家共识提供信息。
BMJ Open. 2023 Feb 1;13(2):e064169. doi: 10.1136/bmjopen-2022-064169.
3
"Calcium bombs" as harbingers of synaptic pathology and their mitigation by magnesium at murine neuromuscular junctions.“钙炸弹”作为突触病理学的预兆及其在小鼠神经肌肉接头处被镁缓解的情况。
Front Mol Neurosci. 2022 Jul 26;15:937974. doi: 10.3389/fnmol.2022.937974. eCollection 2022.
4
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.运动神经元病系统多臂自适应随机试验（MND-SMART）：一项多臂、多阶段、适应性、平台、三期、随机、双盲、安慰剂对照的重新定位药物治疗运动神经元病的试验。
BMJ Open. 2022 Jul 7;12(7):e064173. doi: 10.1136/bmjopen-2022-064173.
5
Advances in Neurodegenerative Diseases.神经退行性疾病的进展
Neurol Int. 2022 Mar 28;14(2):336. doi: 10.3390/neurolint14020027.
本文引用的文献
1
Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.在 UCL MRC 临床试验单位，10 年来在单一方案中测试多种治疗方法：多臂、多阶段平台、伞式和篮子方案。
Clin Trials. 2017 Oct;14(5):451-461. doi: 10.1177/1740774517725697. Epub 2017 Aug 22.
Zotero 插件